Back

Semaglutide reduces volume overload and atrial remodelling in a novel experimental model of cardiometabolic HFpEF

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Therapeutic aspects for hypertension Target Organ Damage/Left Ventricular Hypertrophy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jordyn Thomas

Baker Heart and Diabetes Institute, Melbourne (Australia)

6 More presentations in this session

Presentation thumbnail
Nationwide use of antihypertensive combination therapy in the Czech Republic
Professor J. Vaclavik (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
Dose-response and efficacy ceiling of zilebesiran: a bayesian non-linear spline meta-analysis of phase 1 and KARDIA phase 2 trials
Doctor K. Keswani (Vadodara, IN)
Abstract Slides Video
Presentation thumbnail
Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Autonomous closed-loop intravenous esmolol for systolic blood pressure regulation and beat-to-beat variability suppression with safety supervision: a large-animal validation study
Doctor J. Curneen (Galway, IE)
Abstract Slides Video
Presentation thumbnail
A multidimensional primary care intervention reduces sedentary behaviour and promotes behavioural readiness for physical activity in hypertension and diabetes patients
Doctor M. Marcolino (Belo Horizonte, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Therapeutic aspects for hypertension

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
From obesity and sedentary lifestyle to energetic and metabolic failure: empagliflozin and semaglutide reverse mitochondrial and metabolic dysfunction in experimental HFpEF
30 August 2026
thumbnail
Congress Presentation
Treatment of diastolic dysfunction by targeting beta-adrenergic receptors in vivo in a murine model of cardiometabolic HFpEF
11 May 2024
thumbnail
Congress Presentation
Pharmacotherapy to reduce weight in patients with HFpEF and obesity: what is the latest evidence?
27 August 2023
thumbnail
Congress Presentation
Translational rodent models embracing the complex pathophysiology of heart failure with preserved ejection fraction
11 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources